文献速递脊柱关节炎

既往抗TNF治疗与司库奇尤单抗治疗银屑病关节炎疗效的关联:系统评价与荟萃分析

Association of previous treatment with anti-tumour necrosis factor inhibitors with the effectiveness of secukinumab in the treatment of psoriatic arthritis: systematic review and meta-analysis.
PubMed 文献 · Rheumatology (Oxford) · 2020-01-01

该系统评价与荟萃分析纳入6项报告司库奇尤单抗按既往抗TNFi治疗分层疗效的随机对照试验,比较既往接受抗TNFi治疗者与未接受者的ACR20/ACR50应答。既往抗TNFi暴露组(n=738)33.7%达到ACR20,而未暴露组(n=1754)49.8%达到ACR20,既往抗TNFi治疗与司库奇尤单抗疗效较差显著相关(效应量2.09,95%CI:1.69,2.58)。

要点

  • 既往抗TNFi治疗与司库奇尤单抗治疗PsA的疗效较差显著相关(效应量2.09,95%CI:1.69,2.58)。
  • 既往抗TNFi暴露组ACR20应答率33.7%(249/738),未暴露组49.8%(873/1754)。
  • 部分患者从TNFi转换为司库奇尤单抗仍可获益。

核心结论

  • 部分患者从TNFi转换为司库奇尤单抗可获益,但既往抗TNFi治疗与司库奇尤单抗疗效较差相关。

研究设计与样本

  • 系统评价与荟萃分析,检索PubMed、EMBase、Cochrane library及ClinicalTrials.gov至2020年5月22日。
  • 纳入6项报告司库奇尤单抗按既往抗TNFi治疗分层疗效的随机对照试验。
  • 采用随机效应模型合并疗效数据,以ACR20和ACR50应答为终点。

主要发现

  • 既往抗TNFi暴露组(n=738)33.7%(249/738)达到ACR20应答。
  • 抗TNFi未暴露组(n=1754)49.8%(873/1754)达到ACR20应答。
  • 既往抗TNFi治疗与司库奇尤单抗疗效较差显著相关,效应量2.09(95%CI:1.69,2.58)。

关键数值与推荐

  • ACR20:美国风湿病学会应答标准20%改善。
  • ACR50:美国风湿病学会应答标准50%改善。
  • 效应量2.09(95%CI:1.69,2.58),比较既往抗TNFi治疗与未暴露组对司库奇尤单抗的应答。

临床怎么用

  • 对既往接受过抗TNFi治疗的PsA患者,选择司库奇尤单抗时应预期疗效可能低于未暴露者。
  • 部分既往抗TNFi治疗患者仍可从转换为司库奇尤单抗中获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: We sought to systematically investigate the effectiveness of secukinumab in psoriatic arthritis (PsA) patients who previously received TNFs inhibitor (TNFi) treatment and those who were TNFi naïve. METHODS: Databases (PubMed, EMBase and Cochrane library) and ClinicalTrials.gov were searched from inception to 22 May 2020 for randomized control trails and observational studies of secukinumab, with or without a history of previous anti-TNFi treatment, in PsA. Effectiveness data were extracted and combined using a random-effects meta-analysis. The ACR20 and ACR50 (20% and 50% improvement in American College of Rheumatology response criteria) responses were the endpoints. RESULTS: Six randomized controlled trials that reported the effectiveness of secukinumab by previous anti-TNFi treatment were included. Among patients exposed to a prior anti-TNFi treatment (n = 738), 33.7% (249/738) of patients achieved an ACR20 response. In contrast, in the anti-TNFi-naïve group (n = 1754), 49.8% (873/1754) of patients achieved an ACR20 response. Prior treatment with anti-TNFi was significantly associated with a poorer response to secukinumab compared with the anti-TNFi-naïve group with an effect size of 2.09 (95% CI: 1.69, 2.58). CONCLUSION: Some patients benefit from switching from TNFi to secukinumab, but previous anti-TNFi treatment is associated with poorer effectiveness of secukinumab.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Xu Y, Li Y, Dong M, et al. Association of previous treatment with anti-tumour necrosis factor inhibitors with the effectiveness of secukinumab in the treatment of psoriatic arthritis: systematic review and meta-analysis. Rheumatology (Oxford). 2020. PMID: 33038239. doi:10.1093/rheumatology/keaa449

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。